Phase I trial of a novel intradermal idiotype vaccine in patients with advanced B-cell lymphoma: specific immune responses despite profound immunosuppression

Cancer Research
Cristina BertinettiHendrik Veelken

Abstract

The immunoglobulin receptor of B-cell lymphomas constitutes a specific tumor antigen (idiotype) and a target for active immunotherapy. Encouraging results have been reported in phase II trials after s.c. vaccination of follicular lymphoma patients during clinical remission with idiotype produced from eukaryotic cell lines and coupled to an immunogenic carrier macromolecule. We have developed a good manufacturing protocol for rapid expression of idiotype vaccines as recombinant Fab fragments in Escherichia coli. The objectives of this trial were to show safety and feasibility of intradermal immunization with this vaccine and to investigate whether immune responses were induced by this immunization route. Patients (n = 18) with advanced B-cell malignancies received repetitive intradermal vaccinations with 0.5 to 1.65 mg recombinant idiotype Fab fragment mixed with lipid-based adjuvant in combination with 150 mug granulocyte macrophage colony-stimulating factor s.c. at the same location. The patients' immune status was assessed by flow cytometry of peripheral blood lymphocytes and concomitant hepatitis B vaccination. Cellular and humoral immune responses to the vaccine were assessed by enzyme-linked immunospot and ELISA. Side effe...Continue Reading

References

Jun 1, 1975·The Journal of Experimental Medicine·N Sakato, H N Eisen
May 1, 1986·Journal of Immunological Methods·W L CarrollR Levy
Jan 1, 1981·Cancer·A B MillerA Winkler
Jan 1, 1995·Pharmaceutical Biotechnology·G OttG Van Nest
Jun 7, 1994·Proceedings of the National Academy of Sciences of the United States of America·G F LauritzsenB Bogen
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B D ChesonG P Canellos
Apr 12, 2003·Leukemia & Lymphoma·S ScrivenerA G Prentice
Oct 16, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Wen-Kai WengRonald Levy
Nov 5, 2004·The New England Journal of Medicine·Richard T KenneyGregory M Glenn
Aug 9, 2005·Nature Genetics·Kevin J VerstrepenGerald R Fink
Aug 12, 2005·Current Opinion in Oncology·Sara A Hurvitz, John M Timmerman

❮ Previous
Next ❯

Citations

Sep 18, 2010·Cancer Immunology, Immunotherapy : CII·Max WarnckeHendrik Veelken
Jul 31, 2012·Current Oncology Reports·M Lia Palomba
Sep 18, 2008·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·Javier Briones
May 29, 2007·Oncogene·A López-Díaz de CerioM Bendandi
Jun 3, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Stephen J SchusterLarry W Kwak
Sep 10, 2011·Drugs·Katayoun Rezvani, Hugues de Lavallade
Jun 3, 2014·Journal of Translational Medicine·Tim RoehnischFuat S Oduncu
Jun 1, 2012·Clinical & Developmental Immunology·Ivetta DanyleskoArnon Nagler
Jun 15, 2007·International Reviews of Immunology·Maurizio Chiriva-InternatiW Martin Kast
Nov 5, 2008·Expert Review of Vaccines·John A Mikszta, Philippe E Laurent
Dec 20, 2008·Expert Review of Vaccines·Ascensión López-Díaz de Cerio, Susana Inogés
Dec 8, 2006·Expert Opinion on Biological Therapy·Seung-Tae LeeSattva S Neelapu
Oct 28, 2008·Blood Reviews·Roch Houot, Ronald Levy
Nov 13, 2007·Hematology/oncology Clinics of North America·Rao H Prabhala, Nikhil C Munshi
Apr 22, 2008·British Journal of Haematology·Hyun Jun Park, Sattva S Neelapu
Sep 29, 2011·International Journal of Cancer. Journal International Du Cancer·Claudia WehrMartin Trepel
Mar 20, 2013·Journal of Immunological Methods·Marcelo A NavarreteHendrik Veelken
Feb 28, 2007·Yonsei Medical Journal·Seung-Tae LeeLarry W Kwak
Jul 30, 2020·Protein Engineering, Design & Selection : PEDS·Marcia SticklerFiona A Harding
Aug 26, 2020·Leukemia & Lymphoma·Zijun Y Xu-Monette, Ken H Young
Jul 20, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Osama E RahmaSamir N Khleif
Jan 13, 2021·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jessica LiegelDavid Avigan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.